| First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis. "We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program...continued AMGN UCBJY epoetin Drugs partners |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment